Peter A. Vaccaro

The traditional biopharma approach focused primarily on physician detailing and securing favorable payer contracts, has become inadequate in today’s market.

Market access is about aligning internal strategies with external realities that often change without warning and at a frequency likely not experienced by other biopharma executive roles.

In the race to bolster pipelines and drive growth, biopharma manufacturers are reexamining traditional practices and reimagining market research protocols.

The profitability of biopharma drug launches in the US will remain in decline until manufacturers reimagine their approach with payers

Clinical studies are increasingly designed to satisfy evidentiary needs.

A clearer understanding of the Inflation Reduction Act’s implications is needed for manufacturers to plot a successful course forward.